Drugs / iribrin
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06230055 Background | Jan 2024 → Jan 2026 overdue | Her2-receptor negative breast cancer, malignant leptomeningeal tumor | Fudan University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iribrin | “iribrin(1.4mg/m2, d1,8, q3w, ivgtt)” NCT06230055 ↗ |
| Route | Intravenous | “iribrin(1.4mg/m2, d1,8, q3w, ivgtt)” NCT06230055 ↗ |